BioSpace News Archive

Ionis Pharmaceuticals, Inc. announced that management will participate in virtual fireside chats at the following investor conferences

Bausch Health Companies Inc. announced that the Company will participate in multiple upcoming investor conferences.

ESSA Pharma Inc. today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2021.

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that its Board of Directors has authorized a new share repurchase program under which the Company may repurchase up to $150 million of its outstanding shares of common stock through December 2022.

– LINZESS ® (Iinaclotide) U.S. net sales of $215 million, an increase of 12% year-over-year – –Total revenue of $89 million, an increase of 11% year-over-year, driven primarily by U.S. LINZESS collaboration revenue of $86 million – – GAAP net income of $40 million and adjusted EBITDA of $46 million; ended Q1 2021 with $438 million in cash and cash equivalents –

Aptorum Group Limited, a clinical-stage biopharmaceutical company, has entered into an agreement with Exeltis to develop, manufacture and commercialize a novel preclinical candidate from Aptorum in the following territories: the European Union and Latin America.

Reports Revenue of $1.9 Billion, Growing 22%, and Net Income of $559 Million, or $1.17 per Diluted Share, Increasing 32% and 33%, Respectively, on a Reported Basis for First Quarter 2021 Reports Adjusted Net Income of $603 Million, or Adjusted Diluted EPS of $1.26, for First Quarter 2021

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that its first quarter 2021 financial results will be reported on Thursday, May 13, 2021 before the open of the financial markets. Management will also host a webcast and conference call on May 13, 2021

SARS-CoV-2 Variant Booster Program Update : Single booster dose of 50 µg of mRNA-1273 or mRNA-1273.351 increased neutralizing titers against SARS-CoV-2 and two Variants of Concern (B.1.351, P.1) in previously vaccinated clinical trial participants

Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today that it will present its first-quarter 2021 financial results on May 13. Lars Wegner, CEO of Evaxion, and Glenn Vraniak, CFO, will host an earnings call on May 13 at 8.30 a.m. EDT.